Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus SBRT in HCC with PVTT
NCT04169399Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2019
- Primary completion
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
toripalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04169399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04169399.